Medincell

Medincell ROA

The Return on Assets (ROA) of Medincell (MEDCL.PA) as of Nov 13, 2026 is -28.95 %. In the previous year, Return on Assets (ROA) was -20.38 % — a change of 42.05% (lower).

ROA

-28.95 %

YoY

42.05%

Last updated:

In 2026, Medincell's return on assets (ROA) was -28.95 %, a 42.05% increase from the -20.38 % ROA in the previous year.

The Medincell ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
-51.83 EUR
Jan 1, 2020
-87.58 EUR
Jan 1, 2021
-29.90 EUR
Jan 1, 2022
-55.99 EUR
Jan 1, 2023
-109.10 EUR
Jan 1, 2024
-67.77 EUR
Jan 1, 2025
-20.38 EUR
Jan 1, 2026
-28.95 EUR
The Medincell ROA history
YEARROAYoY
-28.95 %+42.05%
-20.38 %-69.92%
-67.77 %-37.89%
-109.10 %+94.86%
-55.99 %+87.25%
-29.90 %-65.86%
-87.58 %+68.96%
-51.83 %+37.30%
-37.75 %+146.64%
-15.31 %-374.92%
5.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medincell Stock analysis

What does Medincell do? Medincell SA is a leading biotechnology company based in Montpellier, France, specializing in the development and manufacturing of innovative drugs based on its proprietary Intellisome® technology platform. The company was founded in 1999 by Dr. Christophe Douat and has since built an impressive portfolio of products and services. Medincell's business model is based on the development and manufacturing of extended-release drugs through the integration of drugs into the Intellisome® technology platform. This is a novel concept based on the use of polymers that are capable of controlling and slowing down the release of drugs. This allows medications to be administered in a specific dosage and duration, providing greater effectiveness and tolerability for the patient. Medincell has several business areas, including the development of drugs for the treatment of central nervous system (CNS) disorders, including schizophrenia, depression, and chronic pain. The company is also working on the development of drugs for the treatment of infectious diseases and cancer, as well as the development of new technologies for drug manufacturing. Medincell's products include a range of drugs, including Long-Acting Risperidone (a depot preparation for the treatment of schizophrenia), Long-Acting Cabergoline (for the treatment of Parkinson's), and Long-Acting Naltrexone (for the treatment of alcohol and drug addiction). The company also has partnerships with other pharmaceutical companies such as Pierre Fabre, Sanofi, Janssen, and Pfizer for the development of products based on its Intellisome® technology platform. Another important area of Medincell is its service for drug development based on the Intellisome® technology platform. The company offers customers comprehensive support in the development, manufacturing, and approval of extended-release drugs. Customers can choose from a wide range of services, ranging from the identification of active ingredients to the implementation of clinical trials. Overall, Medincell has achieved impressive success in the launch of its products and services based on the Intellisome® technology platform. The company has won several awards for its innovative products and services in the pharmaceutical industry, including the Innovation Award from the European Society of Clinical Microbiology and Infectious Diseases in 2018 and the Excellence in Specialty Pharmaceuticals Award from BioPharm America in 2019. In summary, Medincell SA is a leading company in the biotechnology industry specializing in the development and manufacturing of extended-release drugs based on its Intellisome® technology platform. With an impressive range of products and services and partnerships with several renowned pharmaceutical companies, the company has a promising future as a key player in the pharmaceutical industry. Medincell is one of the most popular companies on Eulerpool.

ROA Details

Understanding Medincell's Return on Assets (ROA)

Medincell's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Medincell's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Medincell's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Medincell’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Medincell stock

Return on Assets (ROA) of Medincell is -28.95 % in 2026.

Return on Assets (ROA) of Medincell changed from -20.38 % to -28.95 %, representing a 42.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Medincell since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Medincell with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medincell

All Key Metrics — Medincell